Convergent human data echo these experimental relationships: circulating desmosine/elastin–breakdown products associate with AAA severity and predict adverse outcomes and future expansion, providing a measurable link between ongoing elastolysis and subsequent growth dynamics [86]. The gene discussed is ELN; the disease is triple-A syndrome.